Updates for Dermatologists and Rheumatologists on PsA Management: Role of IL-17 Inhibitors

IL-17 Inhibitors in the Management of Psoriatic Disease

Agenda

Treat-to-Target in PsA

Early Intervention and Tight Control of Inflammation in Patients With PsA: TICOPA

MDA Criteria

TICOPA: Commonly Reported AEs

Key Domains of PsA

Clinical Challenges to Meeting Treatment Goals in PsA

GRAPPA Treatment Schema for Active PsA

National Psoriasis Foundation: Treatment Targets for Plaque Psoriasis

Overlap of Symptoms in Patients With Psoriatic Disease

Treatment Guidelines and Outcomes for PsA

Evidence-Based Guidelines for the Management of Patients With PsA

Management of Patients With PsA: Domain Involvement Drives Treatment Decisions

Multiple Evidence-Based Guidelines for the Management of Patients With Psoriasis Exist

Incorporating Evidence-Based Guidelines Into Practice: Clinical Challenges

Psoriasis and PsA: Different Manifestations of the Same Disease?

PsA Screening Tools

Multidisciplinary Dermatology-Rheumatology Management of Patients With Psoriasis and PsA

Treatment Considerations for Patients With PsA and Concomitant Comorbidities

PsA Treatment

Clinical Assessments in Patients With Psoriasis

Current and Emerging Biologic Therapy for PsA

Available Biologic Therapy for the Treatment of PsA

Treatment of PsA With IL-17 Inhibitors

Other IL-17 Inhibitors

Anti-IL-23 Agents for the Treatment of PsA

GRAPPA Guidelines: Treatment According to Domain Involvement

GRAPPA Guidelines: Treatment According to Domain Involvement (Cont.)

Multidisciplinary Management of Patients With PsA

Clinical Challenges in the Management of Patients With PsA

Depression in Patients With PsA

Brodalumab

Symptoms of Depression Improve With Appropriate Treatment of Psoriasis

Treatment of PsA and Its Psychosocial Burden

CVD in Patients With PsA

PsA Treatments and the Effect on CV Outcomes

Screen and Manage Modifiable CV Risk Factors to Reduce the Risk for CVD in Patients With PsA

Biological Drugs Used in Psoriasis and PsA During Pregnancy

Secukinumab in Pregnancy: Outcomes From the Global Safety Database

PsA Disease Activity During Pregnancy and the First-Year Postpartum

Program Summary

Program Summary (Cont.)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)